Pfizer (PFE) Price to Earnings (2009 - 2026)

Pfizer (PFE) has reported Price to Earnings for 18 consecutive years, with 581.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Earnings fell 1338.41% year-over-year to 581.7 in Q2 2026; TTM through Jun 2026 was 31.7, a 213.0% increase from a year earlier, with the FY2025 full-year figure at 18.13, down 2.8% from the prior year.
• Price to Earnings was 581.7 for Q2 2026 at Pfizer, down from 57.16 in the prior quarter.
• Over five years, Price to Earnings peaked at 3303.21 in Q2 2024 and troughed at 581.7 in Q2 2026.
• A 5-year average of 217.54 and a median of 39.76 in 2023 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings soared 3629.18% in 2024 and sank 1338.41% in 2026, its largest moves.
• Over 5 years, Price to Earnings stood at 29.62 in 2022, then plunged by 263.34% to 48.38 in 2023, then surged by 144.64% to 21.6 in 2024, then sank by 499.69% to 86.33 in 2025, then slumped by 573.78% to 581.7 in 2026.
• The last three Price to Earnings figures came in at 581.7 (Q2 2026), 57.16 (Q1 2026), and 86.33 (Q4 2025), per Business Quant data.